AI Medical Device Company Aillis Selected for Tokyo's "SusHi Tech Global" Growth Acceleration Program, Phase 1

Aillis Inc. (Headquarters: Chiyoda-ku, Tokyo; Representative Director: Sho Okiyama; hereinafter, "the Company") is pleased to announce its selection as a supported company for the "SusHi Tech Global Growth Acceleration Program (Phase 1)" implemented by the Tokyo Metropolitan Government. We will leverage the financial support and hands-on assistance provided through this program to facilitate the global expansion of the AI medical devices we develop and provide.

■ About the "SusHi Tech Global Growth Acceleration Program"

The Tokyo Metropolitan Government, in its startup strategy "Global Innovation Strategy 2.0 STARTUP & SCALEUP," positions "global" x "scale-up" as a new pillar of its initiatives, promoting the "SusHi Tech Global Project" to intensively support companies aiming for dramatic global growth. Among the SusHi Tech Global initiatives, the "Growth Acceleration Program" Phase 1 has selected startups that are expected to achieve rapid "scale-up" by advancing global expansion at this very moment, providing financial support and tailored hands-on assistance. A total of 10 companies, including ours, have been selected. Selected companies will receive up to 200 million yen in financial support for up to 18 months, tailored hands-on support covering everything from business strategy formulation to overseas travel, and specialized support leveraging expert knowledge and a global network, including in the AI and healthcare sectors.

To date, the Company has been working on digitizing pharyngeal examination data and creating new medical value through data utilization, all through the development and dissemination of AI medical devices. By utilizing the support from this program and the global network of diverse experts, we will accelerate the overseas expansion of Japanese medical AI technology. Moving forward, the Company aims to promote the social implementation of AI medical devices, respond to evolving medical needs worldwide, and build a sustainable cross-border medical infrastructure.

■ About Aillis

Founded in 2017 with the mission of "creating open healthcare that everyone can co-create." Aillis brings together numerous professionals, including its representative and active physician Sho Okiyama, other medical professionals, former government officials from the Ministry of Health, Labour and Welfare and the Ministry of Economy, Trade and Industry, data scientists specializing in AI medical fields, and former employees of major medical device manufacturers. The company develops AI medical devices that digitize doctors' expert skills using deep learning technology (AI technology).

【Company Profile】

・Company Name: Aillis Inc.

・Representative Director: Sho Okiyama

・Business Activities: Development, manufacturing, and sales of AI-powered medical devices, and research and development of machine learning technology

・Established: November 2017

・Head Office Location: 28-4 Kanda Higashimatsushita-cho, Chiyoda-ku, Tokyo 101-0042

・Company URL: https://aillis.jp/